$HRGN
Harvard Apparatus Regenerative Technology Inc

2017 Q1 Form 10-Q Financial Statement

#000114420417026530 Filed on May 11, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1 2015 Q4
Revenue $0.00 $0.00 $8.000K
YoY Change -82.22%
Cost Of Revenue $0.00 $84.00K
YoY Change 265.22%
Gross Profit $0.00 -$76.00K
YoY Change -445.45%
Gross Profit Margin -950.0%
Selling, General & Admin $979.0K $1.094M $930.0K
YoY Change -10.51% -20.61% -41.14%
% of Gross Profit
Research & Development $2.069M $1.378M $1.280M
YoY Change 50.15% 10.95% -0.78%
% of Gross Profit
Depreciation & Amortization $121.0K $111.0K $130.0K
YoY Change 9.01% -0.89% 30.0%
% of Gross Profit
Operating Expenses $3.048M $2.472M $2.214M
YoY Change 23.3% -5.65% -22.7%
Operating Profit -$3.048M -$2.472M -$2.290M
YoY Change 23.3% -5.65% -19.42%
Interest Expense -$790.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$793.0K $0.00 $0.00
YoY Change -100.0%
Pretax Income -$3.841M -$2.472M -$2.290M
YoY Change 55.38% -5.76% -19.42%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.841M -$2.472M -$2.290M
YoY Change 55.38% -5.76% -19.42%
Net Earnings / Revenue -28625.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.824M -$3.479M -$3.418M
COMMON SHARES
Basic Shares Outstanding 14.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.580M $4.850M $7.460M
YoY Change 35.67% -60.12% 41.56%
Cash & Equivalents $6.582M $4.848M $7.456M
Short-Term Investments
Other Short-Term Assets $36.00K $490.0K $0.00
YoY Change -92.65% 81.48%
Inventory $79.00K $75.00K
Prepaid Expenses $249.0K $485.0K $330.0K
Receivables $37.00K $18.00K $21.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $6.900M $5.430M $7.882M
YoY Change 27.07% -57.07% 35.24%
LONG-TERM ASSETS
Property, Plant & Equipment $1.050M $1.135M $1.074M
YoY Change -7.49% -10.56% -21.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.053M $1.135M $1.074M
YoY Change -7.22% -10.56% -21.95%
TOTAL ASSETS
Total Short-Term Assets $6.900M $5.430M $7.882M
Total Long-Term Assets $1.053M $1.135M $1.074M
Total Assets $7.953M $6.565M $8.956M
YoY Change 21.14% -52.83% 24.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $713.0K $264.0K $357.0K
YoY Change 170.08% 1.15% -3.51%
Accrued Expenses $920.0K $120.0K $300.0K
YoY Change 666.67% -70.0% -6.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.430M $388.0K $654.0K
YoY Change 1557.22% -42.43% -7.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.430M $388.0K $654.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $6.430M $388.0K $654.0K
YoY Change 1557.22% -42.43% -7.89%
SHAREHOLDERS EQUITY
Retained Earnings -$27.21M $15.00M
YoY Change 73.78% -215.07%
Common Stock $141.0K $141.0K
YoY Change 39.6% 78.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.523M $6.177M $8.302M
YoY Change
Total Liabilities & Shareholders Equity $7.953M $6.565M $8.956M
YoY Change 21.14% -52.84% 24.32%

Cashflow Statement

Concept 2017 Q1 2016 Q1 2015 Q4
OPERATING ACTIVITIES
Net Income -$3.841M -$2.472M -$2.290M
YoY Change 55.38% -5.76% -19.42%
Depreciation, Depletion And Amortization $121.0K $111.0K $130.0K
YoY Change 9.01% -0.89% 30.0%
Cash From Operating Activities -$3.055M -$2.480M -$1.630M
YoY Change 23.19% 46.75% -29.74%
INVESTING ACTIVITIES
Capital Expenditures $105.0K $128.0K $0.00
YoY Change -17.97% 2033.33% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$105.0K -$130.0K $0.00
YoY Change -19.23% 1200.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.801M 0.000 890.0K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$3.055M -2.480M -1.630M
Cash From Investing Activities -$105.0K -130.0K 0.000
Cash From Financing Activities $6.801M 0.000 890.0K
Net Change In Cash $3.641M -2.610M -740.0K
YoY Change -239.5% -137.88% -69.8%
FREE CASH FLOW
Cash From Operating Activities -$3.055M -$2.480M -$1.630M
Capital Expenditures $105.0K $128.0K $0.00
Free Cash Flow -$3.160M -$2.608M -$1.630M
YoY Change 21.17% 53.77% -25.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
605000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2777000 USD
CY2017Q1 us-gaap Other Assets Current
OtherAssetsCurrent
36000 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
171000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36318000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
212000 USD
CY2017Q1 us-gaap Revenues
Revenues
0 USD
CY2017Q1 us-gaap Assets
Assets
7953000 USD
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
713000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
2777000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
37921000 USD
CY2017Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
917000 USD
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37000 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
1523000 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7953000 USD
CY2016Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1210000 USD
CY2017Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4800000 USD
CY2017Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
249000 USD
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
979000 USD
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
793000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
191000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3841000 USD
CY2017Q1 us-gaap Depreciation
Depreciation
121000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2472000 USD
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1094000 USD
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17108968 shares
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-793000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17108968 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
291000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
347000 USD
CY2016Q1 us-gaap Depreciation
Depreciation
111000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6801000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3641000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2608000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2941000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7456000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-42000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
155000 USD
CY2017Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-176000 USD
CY2016Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
0 USD
CY2017Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2016Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
44000 USD
CY2017Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4800000 USD
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
605000 USD
CY2017Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
3787000 USD
CY2017Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
408000 USD
CY2013Q4 bstg Product Distribution Agreement Term
ProductDistributionAgreementTerm
P10Y
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37116570 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37116570 shares
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6801000 USD
CY2016Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2017Q1 bstg Issuance Of Warrant In Connection With Issuance Of Common Stock
IssuanceOfWarrantInConnectionWithIssuanceOfCommonStock
3787000 USD
CY2016Q1 bstg Issuance Of Warrant In Connection With Issuance Of Common Stock
IssuanceOfWarrantInConnectionWithIssuanceOfCommonStock
0 USD
CY2017Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0201 pure
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0193 pure
CY2017Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0193 pure
CY2017Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.779 pure
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.727 pure
CY2017Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.779 pure
CY2017Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y10M24D
CY2017Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y7M6D
CY2017Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.40
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.76
CY2017Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2017Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
21000000 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1560284 shares
CY2017Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
22560284 shares
CY2017Q1 bstg Class Of Warrant Or Right Issuance Cost
ClassOfWarrantOrRightIssuanceCost
385000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
15000000 USD

Files In Submission

Name View Source Status
0001144204-17-026530-index-headers.html Edgar Link pending
0001144204-17-026530-index.html Edgar Link pending
0001144204-17-026530.txt Edgar Link pending
0001144204-17-026530-xbrl.zip Edgar Link pending
bstg-20170331.xml Edgar Link completed
bstg-20170331.xsd Edgar Link pending
bstg-20170331_cal.xml Edgar Link unprocessable
bstg-20170331_def.xml Edgar Link unprocessable
bstg-20170331_lab.xml Edgar Link unprocessable
bstg-20170331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v466273_10q.htm Edgar Link pending
v466273_ex31-1.htm Edgar Link pending
v466273_ex31-2.htm Edgar Link pending
v466273_ex32-1.htm Edgar Link pending
v466273_ex32-2.htm Edgar Link pending